Concepedia

Author

S. Hegewisch-Becker

Eppendorf (Germany)

Also Known As

Hegewisch-Becker S., Hegewisch-Becker, S., S Hegewisch-Becker, S. Hegewisch-Becker, Susanne Hegewisch-Becker, Susanne Hegewisch‐Becker

78

Publications

1.8K

Citations

22

H-Index

38

Concepts

All Affiliations

Eppendorf (Germany)Universität HamburgRuhr University BochumUniversity Medical Center Hamburg-EppendorfKliniken Maria Hilf
SH

About

S. Hegewisch-Becker is an author at Eppendorf (Germany) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

17

654

2

Health Sciences

4

4

183

3

Gastroenterology

2

2

65

4

Hepatology

2

2

46

5

Cell Biology

1

1

34

S. Hegewisch-Becker

×

24

Publications

1.4K

Citations

20

H-Index

YearCitations

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann,

Annals of Oncology

2016

334

Blood‐based detection of <i><scp>RAS</scp></i> mutations to guide anti‐<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissue‐based <i><scp>RAS</scp></i> testing

Wolff Schmiegel, Rodney J. Scott, S Dooley,

Molecular Oncology

2017

159

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients

Jens Panse, Kay Friedrichs, Alexander Marx,

British Journal of Cancer

2008

125

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André,

Annals of Oncology

2013

101

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann,

International Journal of Cancer

2021

95

Bone Marrow Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

M. Stockshläder, S. Hegewisch-Becker, William Krüger,

Hämatologie und Bluttransfusion

1997

78

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Wolff Schmiegel, A. Reinacher-Schick, Dirk Arnold,

Annals of Oncology

2013

73

Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)

A. Reinacher-Schick, Stefan Kubicka, Werner Freier,

Journal of Clinical Oncology

2008

50

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

Hermann Einsele, M. Bamberg, Wilfried Budach,

Bone Marrow Transplantation

2003

46

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1<sup>st</sup> line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

Florian Lordick, Sylvie Lorenzen, S. Hegewisch-Becker,

Journal of Clinical Oncology

2007

40

Page 1